Login to Your Account

Infinity Extends Hedgehog, PI3K Pact with Mundipharma, Purdue

By Donna Young

Tuesday, December 14, 2010
Infinity Pharmaceuticals Inc. is expected to garner an additional $110 million in 2012, on top of $65 million already banked this year and the $85 million anticipated in 2011, under an expanded deal with Mundipharma International Corp. Ltd., an independent European associated company of Purdue Pharmaceutical Products LP, to develop and commercialize IPI-926, Infinity's Smoothened (Smo) antagonist currently in Phase Ib/II testing, plus candidates arising from its phosphoinositol-3-kinase (PI3K) and discovery programs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription